middle.news
How Bioxyne’s $17.2M Quarter Signals a New Era in Psychedelic and Cannabis Medicines
8:44am on Wednesday 28th of January, 2026 AEDT
•
Healthcare
Read Story
How Bioxyne’s $17.2M Quarter Signals a New Era in Psychedelic and Cannabis Medicines
8:44am on Wednesday 28th of January, 2026 AEDT
Key Points
Record $17.2 million quarterly revenue, up 21% from prior quarter
Positive operating cash flow of $2.5 million in Q2 FY26
Dual listing on Frankfurt Stock Exchange enhances European market access
Exclusive Curaleaf agreement for Que Medical Inhalation Device in Australia
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
BIOXYNE (ASX:BXN)
OPEN ARTICLE